Oliveira Kaísa Menezes, Barreto Eduardo Silva Reis, Alencar Vinicius Borges, Lins-Kusterer Liliane Elze Falcão, Azi Liana Maria Torres de Araujo, Kraychete Durval Campos
School of Medicine, Federal University of Bahia, Salvador, Brazil.
Br J Pain. 2024 Oct;18(5):388-402. doi: 10.1177/20494637241254191. Epub 2024 May 9.
Neuropathic pain (NP) is characterised as a lesion or disease directly affecting the somatosensory system. This study aims to analyse the efficacy of botulinum toxin type A (BT-A) in the treatment of neuropathic pain.
This systematic literature review, guided by PRISMA, applied the PICO strategy with the following criteria: (P = patients with neuropathic pain, I = botulinum toxin, C = placebo or active drug, and O = pain relief).
Fourteen articles, all randomised controlled trials with a placebo control, were included in the review. A total of 645 patients were randomised, with 353 patients receiving treatment with botulinum toxin type A in doses ranging from 25U to 400U. The evaluated studies addressed trigeminal neuralgia, diabetic polyneuropathy, post-herpetic neuralgia, spinal cord injury, phantom limb pain, and peripheral neuropathic pain after trauma or surgery.
BT-A has emerged as a promising treatment for various origins of neuropathic pain. Therefore, future studies should adopt stricter criteria regarding dosage and routes of administration to ensure effective and consistent BT-A application.
神经性疼痛（NP）的特征是直接影响躯体感觉系统的损伤或疾病。本研究旨在分析A型肉毒毒素（BT-A）治疗神经性疼痛的疗效。
本系统文献综述以PRISMA为指导，采用PICO策略，标准如下：（P = 神经性疼痛患者，I = 肉毒毒素，C = 安慰剂或活性药物，O = 疼痛缓解）。
该综述纳入了14篇文章，均为有安慰剂对照的随机对照试验。共有645例患者被随机分组，353例患者接受了剂量为25U至400U的A型肉毒毒素治疗。评估的研究涉及三叉神经痛、糖尿病性多发性神经病变、带状疱疹后神经痛、脊髓损伤、幻肢痛以及创伤或手术后的周围神经性疼痛。
BT-A已成为一种有前景的治疗多种病因神经性疼痛的方法。因此，未来的研究应在剂量和给药途径方面采用更严格的标准，以确保BT-A的有效和一致应用。
